SCOPUS 정보 검색 플랫폼

Volumn 24, Issue 7, 2014, Pages 829-837

Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: Evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and WO2013038390

(1) Norman, Peter a

a NORMAN CONSULTING (United Kingdom)

Author keywords

CF; CFTR; Mucus secretion; Protein transport

Indexed keywords

CHLORIDE CHANNEL; GROWTH HORMONE; IVACAFTOR; LUMACAFTOR; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; OXADIAZOLE DERIVATIVE; PICOLINAMIDE; UNCLASSIFIED DRUG; WO 2013038373; WO 2013038378; WO 2013038381; WO 2013038386; WO 2013038390; AMIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PICOLINIC ACID DERIVATIVE;

ARTICLE; CELL MEMBRANE; CYSTIC FIBROSIS; DRUG STRUCTURE; NONHUMAN; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; PATENT; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; PATENTS AS TOPIC; PICOLINIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903159409 PISSN: 13543776 EISSN: 17447674 Source Type: Journal
DOI: 10.1517/13543776.2014.876412 Document Type: Article

Times cited : (10)

References (26)

1
- 84874726028
- Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
- Derich N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013;22(127):58-65
- (2013) Eur Respir Rev , vol.22 , Issue.127 , pp. 58-65
- Derich, N.¹

2
- 0032912589
- Structure and function of the CFTR chloride channel
- Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79(1 Suppl):S23-45 (Pubitemid 29058908)
- (1999) Physiological Reviews , vol.79 , Issue.1 SUPPL. 1
- Sheppard, D.N.¹ Welsh, M.J.²

3
- 0027162649
- Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
- DOI 10.1016/0092-8674(93)90353-R
- Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73(7):1251-4 (Pubitemid 23201140)
- (1993) Cell , vol.73 , Issue.7 , pp. 1251-1254
- Welsh, M.J.¹ Smith, A.E.²

4
- 33744801247
- Cystic fibrosis gene genetic analysis consortium
- Tsui LC. Cystic fibrosis gene genetic analysis consortium. Hum Mutat 2001;4:167-77
- (2001) Hum Mutat , vol.4 , pp. 167-177
- Tsui, L.C.¹

5
- 79952609106
- Gene therapy for cystic fibrosis
- Davies JC, Alton EW. Gene therapy for cystic fibrosis. Proc Am Thorac Soc 2010;7(6):408-14
- (2010) Proc Am Thorac Soc , vol.7 , Issue.6 , pp. 408-414
- Davies, J.C.¹ Alton, E.W.²

6
- 84885388155
- The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
- Alton EW, Baker A, Baker E, et al. The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep. Biomaterials 2013;34(38):10267-77
- (2013) Biomaterials , vol.34 , Issue.38 , pp. 10267-10277
- Alton, E.W.¹ Baker, A.² Baker, E.³

7
- 84868243529
- Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATPindependent manner
- Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATPindependent manner. J Biol Chem 2012;287(44):36639-49
- (2012) J Biol Chem , vol.287 , Issue.44 , pp. 36639-36649
- Eckford, P.D.¹ Li, C.² Ramjeesingh, M.³ Bear, C.E.⁴

8
- 84883377550
- Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
- O'Reilly R, Elphick HE. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. Drug Des Devel Ther 2013;7:929-37
- (2013) Drug des Devel Ther , vol.7 , pp. 929-937
- O'Reilly, R.¹ Elphick, H.E.²

9
- 33744831154
- Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
- DOI 10.1152/ajplung.00169.2005
- Van Goor F, Straley KS, Cao D, et al. Rescue of delta 508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol 2006;290:L1117-30 (Pubitemid 43830856)
- (2006) American Journal of Physiology - Lung Cellular and Molecular Physiology , vol.290 , Issue.6
- Van Goor, F.¹ Straley, K.S.² Cao, D.³ Gonzalez, J.⁴ Hadida, S.⁵ Hazlewood, A.⁶ Joubran, J.⁷ Knapp, T.⁸ Makings, L.R.⁹ Miller, M.¹⁰ Neuberger, T.¹¹ Olson, E.¹² Panchenko, V.¹³ Rader, J.¹⁴ Singh, A.¹⁵ Stack, J.H.¹⁶ Tung, R.¹⁷ Grootenhuis, P.D.J.¹⁸ Negulescu, P.¹⁹

10
- 81755163563
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108(46):18843-8
- (2011) Proc Natl Acad Sci USA , vol.108 , Issue.46 , pp. 18843-18848
- Van Goor, F.¹ Hadida, S.² Grootenhuis, P.D.³

11
- 20944442087
- Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating
- DOI 10.1124/mol.105.010959
- Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-807 (Pubitemid 40594181)
- (2005) Molecular Pharmacology , vol.67 , Issue.5 , pp. 1797-1807
- Pedemonte, N.¹ Sonawane, N.D.² Taddei, A.³ Hu, J.⁴ Zegarra-Moran, O.⁵ Suen, Y.F.⁶ Robins, L.I.⁷ Dicus, C.W.⁸ Willenbring, D.⁹ Nantz, M.H.¹⁰ Kurth, M.J.¹¹ Galietta, L.J.V.¹² Verkman, A.S.¹³

12
- 41849133213
- 4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing
- DOI 10.1016/j.bmcl.2008.03.037, PII S0960894X08003089
- Yoo CL, Yu GJ, Yang B, et al. 4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing. Bioorg Med Chem Lett 2008;18(8):2610-14 (Pubitemid 351503887)
- (2008) Bioorganic and Medicinal Chemistry Letters , vol.18 , Issue.8 , pp. 2610-2614
- Yoo, C.L.¹ Yu, G.J.² Yang, B.³ Robins, L.I.⁴ Verkman, A.S.⁵ Kurth, M.J.⁶

13
- 84864984030
- Click-based synthesis of triazolobithiazole delta 508-CFTR correctors for cystic fibrosis
- DonaldMB, Rodriguez KX, Shay H, et al. Click-based synthesis of triazolobithiazole delta 508-CFTR correctors for cystic fibrosis. BioorgMed Chem 2012;20(17):5247-53
- (2012) BioorgMed Chem , vol.20 , Issue.17 , pp. 5247-5253
- Donald, M.B.¹ Rodriguez, K.X.² Shay, H.³

14
- 84855202429
- Results of a Phase IIa study of VX-809 an investigational CFTR corrector compound in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
- Clancy JP, Rowe SM, Accurso FJ, et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67(1):12-18
- (2012) Thorax , vol.67 , Issue.1 , pp. 12-18
- Clancy, J.P.¹ Rowe, S.M.² Accurso, F.J.³

15
- 85067731947
- WO113894
- Novartis AG. Pyridine and pyrazine derivative for the treatment of CF. WO113894; 2011
- (2011) Pyridine and Pyrazine Derivative for the Treatment of CF
- Novartis, A.G.¹

16
- 85067738127
- WO029118
- Galapagos NV. Method for identifying compounds useful for increasing the functional activity and cell surface expression of Cf-associated mutant cystic fibrosis transmembrane conductance regulator. WO029118; 2010
- (2010) Method for Identifying Compounds Useful for Increasing the Functional Activity and Cell Surface Expression of Cf-associated Mutant Cystic Fibrosis Transmembrane Conductance Regulator
- Galapagos, N.V.¹

17
- 85067726502
- R&D Update. 2013. Available from
- Galapagos NV, R&D Update. 2013. Available from: www.glpg.com/index. php/download-file/view/1440/1/
- Galapagos, N.V.¹

18
- 85067726185
- Available from
- Galapagos NV. AbbVie and Galapagos to co-develop cystic fibrosis therapies. 2013. Available from: http://www.glpg.com/index.php/download-file/ view/1619/164/
- (2013) AbbVie and Galapagos to Co-develop Cystic Fibrosis Therapies
- Galapagos, N.V.¹

19
- 85067724954
- Available from
- Sun X, Sui J, Qiu J, et al. Available from: http://www.n30pharma.com/ docs/posters/2013-10-15-NACFC-Sun-poster.pdf
- Sun, X.¹ Sui, J.² Qiu, J.³

20
- 85067738862
- WO038373
- Novartis AG. Pyridine amide derivatives. WO038373; 2013
- (2013) Pyridine Amide Derivatives
- Novartis, A.G.¹

21
- 85067738862
- WO038378
- Novartis AG. Pyridine amide derivatives. WO038378; 2013
- (2013) Pyridine Amide Derivatives
- Novartis, A.G.¹

22
- 85067738862
- WO03838
- Novartis AG. Pyridine/pyrazine amide derivatives. WO03838; 2013
- (2013) Pyridine/pyrazine Amide Derivatives
- Novartis, A.G.¹

23
- 85067721044
- WO038386
- Novartis AG. Heterocyclic compounds for the treatment of cystic fibrosis. WO038386; 2013
- (2013) Heterocyclic Compounds for the Treatment of Cystic Fibrosis
- Novartis, A.G.¹

24
- 85067732772
- WO038390
- Novartis AG. N-substituted heterocyclyl carboxamides. WO038390; 2013
- (2013) N-substituted Heterocyclyl Carboxamides
- Novartis, A.G.¹

25
- 84855691925
- Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: Quaternary amines
- Hunt T, Atherton-Watson HC, Axford J, et al. Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines. Bioorg Med Chem Lett 2012;22(2):929-32
- (2012) Bioorg Med Chem Lett , vol.22 , Issue.2 , pp. 929-932
- Hunt, T.¹ Atherton-Watson, H.C.² Axford, J.³

26
- 81755163563
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108(46):18843-87
- (2011) Proc Natl Acad Sci USA , vol.108 , Issue.46 , pp. 18843-18887
- Van Goor, F.¹ Hadida, S.² Grootenhuis, P.D.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.